569 reports of this reaction
2.4% of all DALTEPARIN SODIUM reports
#3 most reported adverse reaction
PULMONARY EMBOLISM is the #3 most commonly reported adverse reaction for DALTEPARIN SODIUM, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 569 FDA adverse event reports linking DALTEPARIN SODIUM to PULMONARY EMBOLISM. This represents approximately 2.4% of all 23,703 adverse event reports for this drug.
Patients taking DALTEPARIN SODIUM who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is a less commonly reported adverse event for DALTEPARIN SODIUM, but still significant enough to appear in the safety profile.
In addition to pulmonary embolism, the following adverse reactions have been reported for DALTEPARIN SODIUM:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 569 FDA reports for DALTEPARIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 2.4% of all adverse event reports for DALTEPARIN SODIUM, making it one of the most commonly reported side effect.
If you experience pulmonary embolism while taking DALTEPARIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.